GSK (GlaxoSmithKline) 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q3 2026 sales increased 5% to 8.9 billion pounds, core operating profit grew 5%, and core earnings per share increased 1%.
- Specialty medicines grew 15%, led by launches and growth drivers including Cabinova, up 35%; Apertute, up 21%; and Nucala, up 18%.
- Vaccine performance declined 2%, partly due to Shingrix China destocking, while the meningitis portfolio grew 12%; general medicines were flat.
- Year-to-date cash generation remained strong, with CGFO 1.1 billion pounds ahead of last year and free cash flow up 1.8 billion year-to-date.
- The quarter included 0.3 of a billion accelerate growth charges; GSK now expects charges of up to 1 billion pounds in 2026.
- R&D increased 22%, with 18 phase 3 studies started in 2026 and a further 4 on track to start before year-end.
- Jai Detro generated 3 million pounds following its first launch in non-small cell lung cancer; Hipsargo was approved in the US and Japan, and Gem Pearly received accelerated approval for locally advanced rectal cancer.
- Management reported Q3 sales growth of 5% and core operating profit growth of 5%, with operating margin broadly stable.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome, everyone, and thanks for joining GSK's Q3 2026 results. Today's call will last approximately one hour, with the presentation taking around 30 minutes and the remaining time for your questions. Before we begin, this slide is our usual safe harbor statement. We will comment on our performance using constant exchange rates or CER, unless otherwise stated. I will now hand over to Luke Miels, CEO.
Thanks, Jeff. I am joined today by Tony Wood, who will give an update on the pipeline, Nina Mojas, who will cover growth drivers, Julie Brown, who will cover financial performance, and David Redfern will join for Q&A. First, let's review the company performance. Next slide, please. Q3 was strong and we have continued operational momentum with sales up 5% to GBP 8.9 billion. As expected, specialty is driving our momentum, including launches in respiratory and oncology. Core operating profit grew 5% and core earnings per share were up 1%. Our cash generation remains very positive at GBP 7.4 billion year to date. Our Q3 dividend is 17 pence and we are on track with our responsible business rating. Given our operating momentum and launch progress, we are pleased to reconfirm 2026 guidance today. Next slide, please. This slide is a reminder of our key priorities to drive value for the business and our shareholders.
To start, we are focused on maximizing launches. This quarter, we have made good progress on Blenrep, where repeat prescribers are growing as physicians and patients get comfortable using the medicine, and Exdensur, where we are seeing momentum building with prescribers, patients, and access all increasing in the quarter. We have now also had our first launch in non-small cell lung cancer with Jideytro for TKI pretreated ROS1 positive patients, which has already delivered GBP 3 million. Our oncology portfolio continues to grow with a further indication for Jemperli in locally advanced rectal cancer. We also received approval for Hibsago in the U.S. and Japan, the first finite treatment to offer a functional cure for patients with chronic hepatitis B. Each of these products will meaningfully contribute to near-term growth as we continue to build momentum in our specialty business.
At quarter 2, we outlined clear plans to accelerate R&D and we are now delivering on those plans. We are recruiting in 18 of the 22 phase III trial starts for 2026, including two new phase III studies for flu and the rest on track to start recruiting before the end of the year. We also presented data for several of these assets, including Jideytro, Ris-Rez, Mo-Rez, and Jemperli, demonstrating significant progress in our oncology pipeline and proof points for our approach to BD. Finally, on simplification, we have made progress on the Accelerate Growth program, helping to reallocate resources to invest in R&D and accelerate our late-stage development pipeline. Fundamentally, this will align our cost base with our evolving portfolio and help us accelerate growth and deliver value for patients and shareholders. With that, I will now hand over to Tony to cover our pipeline momentum in more detail.
Thanks, Luke. It has been a busy period for R&D with a number of recent approvals and pivotal data readouts. Jideytro and Hibsago approvals were received ahead of their FDA PDUFA dates and Jemperli received accelerated approval for rectal cancer. These, together with the strength of the data presented at recent medical congresses, demonstrate the value of assets in our late-stage pipeline, where the majority have potential to be best in class and where we have added 12 new phase III study starts this quarter, bringing us to 18 for the year. Next slide, please. Moving to new products and indications. Jideytro for ROS1 positive and neladalkib for ALK-positive mutations in non-small cell lung cancer have the potential to meaningfully improve on standard of care. These mutations represent 3%-5% of all non-small cell lung cancer.
Here, patients are often younger, in their 40s and 50s, and remain on therapy for years while experiencing high rates of central nervous system side effects and often developing brain metastases. Importantly, Jideytro is the first and only ROS1 TKI to address both selective targeting of ROS1 resistance mutations and CNS activity, thus aiming to improve treatment for patients with brain metastases while minimizing TRK-related CNS adverse events. Similarly, neladalkib is a once-a-day medicine designed to avoid off-target adverse events, which can be treatment limited for patients. We anticipate FDA approval in November, supported by the ALKOVE study, which showed a median progression-free survival of 14.5 months in a previously TKI-treated population. Also in oncology, approval for Jemperli in locally advanced rectal cancer is based on the AZUR-1 data, which shows 68% of participants with no detectable signs of cancer one year or more after treatment.
Current standard of care achieves complete clinical response in around 20%-25% of cases and can have lasting consequences, including bowel and urinary dysfunction and secondary cancers. And finally for Hibsago. Nina will cover our launch plans for this important medicine in a moment, but I want to reiterate how transformational Hibsago will be for those living with chronic hepatitis B. These patients are at an increased risk of death from cirrhosis and liver cancer, and current treatment options involve lifelong therapy. Hibsago is the first finite treatment for chronic hepatitis B, which provides the potential for a functional cure. We plan to share additional data from the development program at AASLD in November. Now moving to our development plans for Jideytro and neladalkib in TKI-naive patients. Jideytro data were presented at the recent World Conference on Lung Cancer.
The ARROS-1 response rates are amongst the highest ever reported in this patient population, with a 94% overall response rate and a 15% complete response rate. The median duration of response has not yet been reached, but 86% of patients have a duration of response of greater than 12 months. Data on brain metastases in this TKI-naive population show no CNS progression events observed in patients without metastases at baseline, and a 100% response rate in those with brain metastases at study entry. The emerging clinical profile for Jideytro suggests it has the potential to deliver meaningful outcomes as a best-in-class therapy for TKI-naive patients. Neladalkib is also in development for a TKI-naive population, and here the phase I/II ALKOVE study shows an 86% overall response rate. Median duration of response has not yet been reached.
However, 91% of patients have a duration greater than 12 months, as you can see on this slide. The corresponding phase III TKI-naive study, ALKAZAR, is more than 50% recruited. Based on available data today, we believe neladalkib could have the potential to drive years of progression-free survival. Next slide, please. Next for Ris-Rez, where emerging data demonstrate robust and consistent outcomes across a range of solid tumor types. In small cell lung cancer, the Chinese phase III ARTEMIS-008 data presented at World Conference on Lung Cancer by Hansoh showed a 54% reduction in risk of death and a median overall survival of 18.5 months. The global pan-tumor phase I/II EMBOLD 101 study has now enrolled with more than 550 patients.
Data from the small cell lung cancer cohort of this study were presented last weekend at ESMO and showed a 61% response rate, consistent with the 58% overall response rate observed in ARTEMIS-008. The global phase III trial, EMBOLD SCLC-301, is also recruiting well, and we anticipate preliminary data by the end of 2027. Next slide, please. Also for Ris-Rez, data from the Hansoh phase III ARTEMIS-011 study, which looked at Ris-Rez versus standard of care in Chinese patients with relapsed refractory osteosarcoma, was selected for the presidential symposium at ESMO this week. Osteosarcoma is a rare tumor, and relapsed patients have few treatment options. The current standard of care delivers around 2% response rate and 1.5 months of progression-free survival. In this trial, Ris-Rez demonstrated a 67% reduction in risk of disease progression or death in patients with relapsed disease.
A global GSK phase II trial, EMBOLD Sarcoma-202, started earlier this year and is recruiting well. The global EMBOLD program has now over 1,000 patients who have received Ris-Rez, with more than half of those enrolled in the past eight months. Over the next 12 months, we anticipate data readouts across multiple indications, and we look forward to sharing these as they mature. Next slide, please. For Mo-Rez, new data presented at ESMO from the global phase I BEHOLD-1 trial confirms the potential for best-in-class activity in ovarian cancer, with median progression-free survival of around 11 months in a non-biomarker selected population. These data compare favorably with current standard of care, which delivers around six to eight months of PFS. As promised at the Accelerate Growth Event in July, we have now started recruitment for five phase III trials in ovarian and endometrial cancer.
Over the next 12 months, alongside Hansoh, we will continue to generate longer-term data to demonstrate the durability, response, and safety profile of this novel ADC. Next slide, please. Also at ESMO, we presented interim pivotal results from AZUR-1, which looked at Jemperli in the treatment of patients with dMMR locally advanced rectal cancer. The current standard of care for these patients achieves a complete clinical response in around 20%-25% of cases but involves chemotherapy, radiotherapy, and surgery and is associated with significant morbidity. In AZUR-1, over two-thirds of patients achieved a complete clinical response, and after a two-year follow-up period, no disease recurrences were reported amongst patients who responded. The study continues to generate data and offers an important, potentially curative option for patients with locally advanced rectal cancer. Next slide, please. Turning now to vaccines.
Last season, over 700,000 people, mostly older adults, were hospitalized with flu in the U.S. Currently, flu vaccines, which generally focus on hemagglutinin, protect unevenly. Our mRNA flu vaccine candidate, which has achieved Fast Track designation from the FDA, targets both hemagglutinins and neuraminidase. Neuraminidase changes more slowly, so protection may be more durable when strains mismatch. Targeting both has the potential to offer broader immunity and better, more consistent protection. In phase II, our candidate produced stronger immune responses against both targets than a high-dose comparator, supporting our decision to start a large phase III study in more than 50,000 adults aged 65 and over. The study started in September, and more than two-thirds of this season's enrollment target has already been recruited. This study will run over two seasons, and we anticipate preliminary data next year, pending a sufficient number of cases. Next slide, please. Across R&D, we continue to make fantastic progress in accelerating our late-stage pipeline.
At Q2, we described our plans to start 20-plus phase III studies in 2026. We've now started 18 phase III studies, with a further four on track to start before the end of the year. These studies have been accelerated based on our confidence in the differentiation and benefit to patients of our late-stage assets. I'm pleased with the continued hard work of our teams to deliver this previously unmatched pace of acceleration across a broad and growing portfolio. Next slide, please. Before I close, I momentarily want to share this slide, which we presented in July. It demonstrates the expansion of the late-stage portfolio, and from 2028 onwards, we expect to build further as we progress phase I and II studies and continue to pursue external opportunities.
I'll now hand over to Nina to cover commercial performance.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
